5-Amino-1MQ
NNMT Inhibitor (Small Molecule) - Small-molecule NNMT inhibitor studied in metabolism research.
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), a target studied in adipocyte-metabolism and cellular-energy research.
It is the one entry here that is not a peptide, and that changes the whole record: no amino-acid sequence, a defined small-molecule formula, and enzyme inhibition rather than receptor binding as the mechanism under study. Sitting upstream of the NAD⁺ salvage pathway is why it is frequently run alongside NAD⁺ itself in metabolism research.
5-Amino-1MQ specifications
- CAS number
- 42464-96-0
- Molecular formula
- C10H11IN2 (iodide salt)
- Molecular weight
- 286.11 g/mol
- Sequence
- 5-amino-1-methylquinolinium (small molecule)
- Residues
- Small molecule
- Presentation
- Lyophilized powder
- Documented purity
- 99.94% by HPLC
- Available sizes
- 50mg ($80)
- Archived COA lots
- 8
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- NNMT inhibition - Studied for modulation of NAD⁺ salvage and adipocyte energy metabolism.
Reported mechanisms in the literature
- NNMT inhibition - A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), studied for modulation of the NAD⁺ salvage pathway and adipocyte energy metabolism. (Kraus et al.)
What 5-Amino-1MQ is researched for
- Adipocyte energy - Studied as an NNMT inhibitor for adipocyte-metabolism and energy-handling endpoints. (Kraus et al.)
- NAD⁺ salvage - Investigated for modulation of the NAD⁺ salvage pathway downstream of NNMT. (Preclinical literature)
5-Amino-1MQ certificates of analysis on file
Every lot below was tested by an independent laboratory and the full report is published as a PDF. Purity is shown exactly as the report states it. The same records are searchable in the COA library and can be checked on the lot verification page.
| Lot | Tested | Size | Laboratory | HPLC purity | Identity | Certificate |
|---|---|---|---|---|---|---|
| 2CTMHE | 15 Sep 2026 | 50mg | Freedom Diagnostics | 99.91% | Confirmed (LC-MS/MS) | COA PDF |
| D778RG | 19 Aug 2026 | 50mg | Accurate Test Labs | 99.77% | Confirmed (LC-MS/MS) | COA PDF |
| 5A100-WM2607-001 | 13 Aug 2026 | 100mg | Accurate Test Labs | 99.19% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2605110195 | 11 May 2026 | 50mg | Freedom Diagnostics | 99.94% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2604200520 | 20 Apr 2026 | 50mg | Freedom Diagnostics | 99.77% | Confirmed (LC-MS/MS) | COA PDF |
| PWIU5B | 10 Apr 2026 | 50mg | Freedom Diagnostics | 99.74% | Confirmed (LC-MS/MS) | COA PDF |
| AM50-11132025-J | 16 Nov 2025 | 50mg | Freedom Diagnostics | 99.42% | Confirmed (LC-MS/MS) | COA PDF |
| FD-2511140004 | 14 Nov 2025 | 50mg | Freedom Diagnostics | 99.42% | Confirmed (LC-MS/MS) | COA PDF |
Published literature on 5-Amino-1MQ
The mechanisms above trace to peer-reviewed studies indexed on PubMed. These are independent third-party publications, not Aspect Peptides claims. Browse indexed research on PubMed.
Research notes: 5-Amino-1MQ
Background
5-Amino-1MQ (5-amino-1-methylquinolinium) is not a peptide. It is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide using S-adenosylmethionine. NNMT has been studied as a regulator of adipocyte energy metabolism: knocking it down in white adipose tissue and liver protected mice from diet-induced obesity (Kraus et al., 2014), and a series of membrane-permeable methylquinolinium inhibitors reversed high-fat-diet-induced obesity in mice (Neelakantan et al., 2018). Because NNMT draws on the same nicotinamide pool as the NAD+ salvage pathway, it is often studied next to NAD+ itself.
What the Aspect certificates show
There are 8 certificate records for the 50mg and 100mg vials, from two laboratories (Freedom Diagnostics and Accurate Test Labs), dated 14 November 2025 to 15 September 2026. Reported HPLC purity runs from 99.19% to 99.94%. Identity is confirmed by LC-MS/MS. It is supplied as an orange lyophilized powder. Being a defined small molecule, it has a formula (C10H11IN2, iodide salt) and molecular weight (286.11 g/mol) rather than a sequence. Each full report is available as a PDF on this page and in the COA library.
How it differs from related compounds
NAD+ is the metabolite in the pathway this enzyme feeds; 5-Amino-1MQ is studied as an upstream modulator rather than a replacement. MOTS-c is a mitochondrial-derived peptide studied in cellular energy research through a different mechanism.
Citations
Kraus D et al., Nature 2014 (PMID 24717514). Neelakantan H et al., Biochem Pharmacol 2018 (PMID 29155147).
Third-party publications are cited for context and are not Aspect Peptides claims. For laboratory research use only.
5-Amino-1MQ frequently asked questions
What is 5-Amino-1MQ?
A small-molecule inhibitor of the enzyme NNMT, a target studied in adipocyte-metabolism and cellular-energy research. It is most commonly supplied as the iodide salt.
Is it approved for human use?
No. It is a research chemical only, with preclinical data only, supplied for in-vitro laboratory study.
What is it researched for?
NNMT inhibition and its downstream effects on NAD⁺ metabolism and adipocyte energy handling in cell and animal models.
Documented to 99.94% purity by HPLC · third-party COA every lot · from $80 · For laboratory research use only.
Related Metabolic compounds
- GLP-1 S - Single-agonist GLP-1 research compound.
- GLP-3 RT - Triple-receptor GLP research compound (GLP-1/GIP/glucagon class).
- GLP-2 TZ - Dual GIP/GLP-1 receptor co-agonist studied in glucose-handling and energy-balance research.
- Cagrilintide - Acylated amylin analogue studied for amylin and calcitonin receptor signaling.
- GLP-3 RT + Cagri - GLP-3 RT (10mg) co-formulated with Cagrilintide (2mg) in one vial.
- MOTS-c - Mitochondrial-derived peptide studied for metabolic regulation.